CAPRICOR THERAPEUTICS INC. - COMMON STOCK

18,62

22-ноября-24 16:44:58

15 мин. задержка

Акции

+0,83

+4,67%

Сегодняшний диапазон

17,51 - 18,88

ISIN

N/A

Источник

NASDAQ

Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis

11 дек 2023 09:00:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

14 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14

07 ноя 2023 09:15:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program

19 окт 2023 16:01:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society

10 окт 2023 09:00:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Announces $23 Million Registered Direct Offering

29 сен 2023 07:35:51 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy

29 сен 2023 07:30:58 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors

06 сен 2023 09:00:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 авг 2023 16:05:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7

02 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors

13 июл 2023 08:30:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

30 июн 2023 09:25:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy

13 июн 2023 09:15:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

07 июн 2023 09:15:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 май 2023 16:01:01 Источник Nasdaq GlobeNewswire
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11

04 май 2023 09:00:01 Источник Nasdaq GlobeNewswire
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform

27 апр 2023 09:00:01 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

23 мар 2023 09:25:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 мар 2023 16:01:00 Источник Nasdaq GlobeNewswire
Capricor Therapeutics to Present Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Update on March 15

08 мар 2023 09:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.